CBS domains form energy-sensing modules whose binding of adenosine ligands is disrupted by disease mutations

Journal of Clinical Investigation

Volumn 113, Issue 2, 2004, Pages 274-284

  Scott, John W ^a   Hawley, Simon A ^a   Green, Kevin A ^a   Anis, Miliea ^a   Stewart, Greg ^a   Scullion, Gillian A ^a   Norman, David G ^a   Hardie, D Grahame ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ADENOSINE PHOSPHATE; ADENOSINE TRIPHOSPHATE; CHLORIDE CHANNEL; CYSTATHIONINE BETA SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INOSINATE DEHYDROGENASE; LIGAND; S ADENOSYLMETHIONINE; COMPLEMENTARY DNA; DNA; GLUTATHIONE TRANSFERASE; HYBRID PROTEIN; ISOPROTEIN; RECOMBINANT PROTEIN;

ARTICLE; BARTTER SYNDROME; CBS DOMAIN; CELL ENERGY; GENE MUTATION; GENERALIZED EPILEPSY; GENETIC DISORDER; HOMOCYSTINURIA; HUMAN; HYPERCALCIURIA; LIGAND BINDING; MUTATION; NEPHROLITHIASIS; NONHUMAN; NUCLEOTIDE BINDING SITE; PRIORITY JOURNAL; PROTEIN DOMAIN; RETINITIS PIGMENTOSA; THOMSEN DISEASE; WOLFF PARKINSON WHITE SYNDROME; ANIMAL; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; DIMERIZATION; DOSE RESPONSE; ESCHERICHIA COLI; KINETICS; LIVER; METABOLISM; MOLECULAR CLONING; PATHOLOGY; PLASMID; POLYMERASE CHAIN REACTION; PROTEIN BINDING; PROTEIN MOTIF; PROTEIN TERTIARY STRUCTURE; RAT;

ADENOSINE; ADENOSINE MONOPHOSPHATE; ADENOSINE TRIPHOSPHATE; ALLOSTERIC SITE; AMINO ACID MOTIFS; ANIMALS; BINDING SITES; CLONING, MOLECULAR; DIMERIZATION; DNA; DNA, COMPLEMENTARY; DOSE-RESPONSE RELATIONSHIP, DRUG; ESCHERICHIA COLI; GLUTATHIONE TRANSFERASE; HUMANS; KINETICS; LIGANDS; LIVER; MODELS, MOLECULAR; MUTATION; PLASMIDS; POLYMERASE CHAIN REACTION; PROTEIN BINDING; PROTEIN ISOFORMS; PROTEIN STRUCTURE, TERTIARY; RATS; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS; RETINITIS PIGMENTOSA;

EID: 85047691317     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI19874     Document Type: Article

References (52)

1. Bateman, A. 1997. The structure of a domain common to archaebacteria and the homocystinuria disease protein. Trends Biochem. Sci. 22:12-13.
2. Kluijtmans, L.A., et al. 1996. Defective cystathionine β-synthase regulation by S-adenosylmethionine in a partially pyridoxine responsive homocystinuria patient. J. Clin. Invest. 98:285-289.
3. Bowne, S.J., et al. 2002. Mutations in the inosine monophosphate dehydrogenase 1 gene (IMPDH1) cause the RP10 form of autosomal dominant retinitis pigmentosa. Hum. Mol. Genet. 11:559-568.
4. Kennan, A., et al. 2002. Identification of an IMPDH1 mutation in autosomal dominant retinitis pigmentosa (RP10) revealed following comparative microarray analysis of transcripts derived from retinas of wild-type and Rho(-/-) mice. Hum. Mol. Genet. 11:547-557.
5. Pusch, M. 2002. Myotonia caused by mutations in the muscle chloride channel gene CLCN1. Hum. Mutat. 19:423-434.
6. Haug, K., et al. 2003. Mutations in CLCN2 encoding a voltage-gated chloride channel are associated with idiopathic generalized epilepsies. Nat. Genet. 33:527-532.
7. Lloyd, S.E., et al. 1997. Characterisation of renal chloride channel, CLCN5, mutations in hypercalciuric nephrolithiasis (kidney stones) disorders. Hum. Mol. Genet. 6:1233-1239.
8. Konrad, M., et al. 2000. Mutations in the chloride channel gene CLCNKB as a cause of classic Bartter syndrome. J. Am. Soc. Nephrol. 11:1449-1459.
9. Gollob, M.H., et al. 2001. Novel PRKAG2 mutation responsible for the genetic syndrome of ventricular preexcitation and conduction system disease with childhood onset and absence of cardiac hypertrophy. Circulation. 104:3030-3033.
10. Gollob, M.H., et al. 2001. Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. N. Engl. J. Med. 344:1823-1831.
11. Blair, E., et al. 2001. Mutations in the gamma-2 subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis. Hum. Mol. Genet. 10:1215-1220.
12. Arad, M., et al. 2002. Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. J. Clin. Invest. 109:357-362. doi:10.1172/JCI200214571.
13. Milan, D., et al. 2000. A mutation in PRKAG3 associated with excess glycogen content in pig skeletal muscle. Science. 288:1248-1251.
14. Hardie, D.G., and Hawley, S.A. 2001. AMP-activated protein kinase: the energy charge hypothesis revisited. Bioessays. 23:1112-1119.
15. Song, X.M., et al. 2002. 5-Aminoimidazole-4-carboxamide ribonucleoside treatment improves glucose homeostasis in insulin-resistant diabetic (ob/ob) mice. Diabetologia. 45:56-65.
16. Buhl, E.S., et al. 2002. Long-term AlCAR administration reduces metabolic disturbances and lowers blood pressure in rats displaying features of the insulin resistance syndrome. Diabetes. 51:2199-2206.
17. Iglesias, M.A., et al. 2002. AlCAR administration causes an apparent enhancement of muscle and liver insulin action in insulin-resistant high-fat-fed rats. Diabetes. 51:2886-2894.
18. Bergeron, R., et al. 2001. Effect of 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats. Diabetes. 50:1076-1082.
19. Winder, W.W., and Hardie, D.G. 1996. Inactivation of acetyl-CoA carboxylase and activation of AMP-activated protein kinase in muscle during exercise. Am. J. Physiol. 270:E299-E304.
20. Merrill, G.M., Kurth, E., Hardie, D.G., and Winder, W.W. 1997. AlCAR decreases malonyl-CoA and increases fatty acid oxidation in skeletal muscle of the rat. Am. J. Physiol. 273:E1107-E1112.
21. Zhou, G., et al. 2001. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108:1167-1174. doi:10.1172/JC1200113505.
22. Hawley, S.A., Gadalla, A.E., Olsen, G.S., and Hardie, D.G. 2002. The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes. 51:2420-2425.
23. Fryer, L.G., Parbu-Patel, A., and Carling, D. 2002. The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct pathways. J. Biol. Chem. 277:25226-25232.
24. Minokoshi, Y., et al. 2002. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature. 415:339-343.
25. Yamauchi, T., et al. 2002. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med. 6:1288-1295.
26. Winder, W.W., and Hardie, D.G. 1999. AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am. J. Physiol. 277:E1-E10.
27. Moller, D.E. 2001. New drug targets for type 2 diabetes and the metabolic syndrome. Nature. 414:821-827.
28. Cheung, P.C.F., Salt, I.P., Davies, S.P., Hardie, D.G., and Carling, D. 2000. Characterization of AMP-activated protein kinase γ subunit isoforms and their role in AMP binding. Biochem. J. 346:659-669.
29. Woods, A., et al. 1996. Characterization of AMP-activated protein kinase β and γ subunits: assembly of the heterotrimeric complex in vitro. J. Biol. Chem. 271:10282-10290.
30. Woods, A., Salt, I., Scott, J., Hardie, D.G., and Carling, D. 1996. The α1 and α2 isoforms of the AMP-activated protein kinase have similar activ-ities in rat liver but exhibit differences in substrate specificity in vitro. FEBS Lett. 397:347-351.
31. Hardie, D.G., Salt, I.P., and Davies, S.P. 2000. Analysis of the role of the AMP-activated protein kinase in the response to cellular stress. Methods Mol. Biol. 99:63-75.
32. Stein, S.C., Woods, A., Jones, N.A., Davison, M.D., and Carling, D. 2000. The regulation of AMP-activated protein kinase by phosphorylation. Biochem. J. 345:437-443.
33. Janosik, M., Kery, V., Gaustadnes, M., Maclean, K.N., and Kraus, J.P. 2001. Regulation of human cystathionine beta-synthase by S-adenosyl-L-methionine: evidence for two catalytically active conformations involving an autoinhibitory domain in the C-terminal region. Biochemistry. 40:10625-10633.
34. Zhang, R., et al. 1999. Characteristics and crystal structure of bacterial inosine-S′-monophosphate dehydrogenase. Biochemistry. 38:4691-4700.
35. Corton, J.M., Gillespie, J.G., Hawley, S.A., and Hardie, D.G. 1995. 5-Aminoimidazole-4-carboxamide ribonucleoside: a specific method for activating AMP-activated protein kinase in intact cells? Eur. J. Biochem. 229:558-565.
36. Hamilton, S.R., et al. 2001. An activating mutation in the γ1 subunit of the AMP-activated protein kinase. FEBS Lett. 500:163-168.
37. Daniel, T.D., and Carling, D. 2002. Functional analysis of mutations in the γ2 subunit of AMP-activated protein kinase associated with cardiac hypertrophy and Wolff-Parkinson-White syndrome. J. Biol. Chem. 277:51017-51024.
38. Wilson, W.A., Hawley, S.A., and Hardie, D.G. 1996. The mechanism of glucose repression/derepression in yeast: SNF1 protein kinase is activated by phosphorylation under derepressing conditions, and this correlates with a high AMP:ATP ratio. Curr. Biol. 6:1426-1434.
39. Gilbert, H.J., Lowe, C.R., and Drabble, W.T. 1979. Inosine 5′-monophosphate dehydrogenase of Escherichia coli. Purification by affinity chromatography, subunit structure and inhibition by guanosine 5′-monophosphate. Biochem. J. 183:481-494.
40. Sintchak, M.D., et al. 1996. Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid. Cell. 85:921-930.
41. Fetler, L., and Vachette, P. 2001. The allosteric activator Mg-ATP modifies the quaternary structure of the R-state of Escherichia coli aspartare transcarbamylase without altering the T↔R equilibrium. J. Mol. Biol. 309:817-832.
42. Vanoye, C.G., and George, A.G., Jr. 2002. Functional characterization of recombinant human ClC-4 chloride channels in cultured mammalian cells. J. Physiol. 539:373-383.
43. Shan, X., Dunbrack, R.L., Jr., Christopher, S.A., and Kruger, W.D. 2001. Mutations in the regulatory domain of cystathionine β-synthase can functionally suppress patient-derived mutations in cis. Hum. Mol. Genet. 10:635-643.
44. Kery, V., Poneleit, L., and Kraus, J.P. 1998. Trypsin cleavage of human cystathionine β-synthase into an evolutionarily conserved active core: structural and functional consequences. Arch. Biochem. Biophys. 355:222-232.
45. Evande, R., Blom, H., Boers, G.H., and Banerjee, R. 2002. Alleviation of intrasteric inhibition by the pathogenic activation domain mutation, D444N, in human cystathionine beta-synthase. Biochemistry. 41:11832-11837.
46. Bateman, A., et al. 2002. The Pfam protein families database. Nucleic Acids Res. 30:276-280.
47. Oliveriusova, J., Kery, V., Maclean, K.N., and Kraus, J.P. 2002. Deletion mutagenesis of human cystathionine beta-synthase. Impact on activity, oligomeric status, and S-adenosylmethionine regulation. J. Biol. Chem. 277:48386-48394.
48. Su, Y., et al. 1995. Regulatory subunit of protein kinase A: structure of deletion mutant with cAMP binding domains. Science. 269:807-813.
49. Jhee, K.H., McPhie, P., and Miles, E.W. 2000. Yeast cystathionine betasynthase is a pyridoxal phosphate enzyme but, unlike the human enzyme, is not a heme protein. J. Biol. Chem. 275:11541-11544.
50. Maclean, K.N., Janosik, M., Olivetiusova, J., Kery, V., and Kraus, J.P. 2000. Transsulfuration in Saccharomyces cerevisiae is not dependent on heme: purification and characterization of recombinant yeast cystathionine beta-synthase. J. Inorg. Biochem. 81:161-171.
51. Nicholls, A., Sharp, K.A., and Honig, B. 1991. Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons. Proteins. 11:281-296.
52. Sali, A., and Blundell, T.L. 1993. Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 234:779-815.